

Humira® 40 mg – יומירה 40 מ"ג- עט מוכן להזרקה באריזת עט משופרת
 Solution for injection in Pre-filled Pen
 תמיסה להזרקה בעט מוכן להזרקה
 Adalimumab 40 mg / 0.8 ml

חברת Abbvie biopharmaceuticals Ltd, ישראל משיקה מנגנון עט משופר עבור התכשיר Humira - "עט מוכן להזרקה" באישור משרד הבריאות.

אין כל שינוי בהנחיות ההזרקה.

מנגנון העט המשופר מבטיח את הפעלת מנגנון ההזרקה בצורה מיטבית ומפחית הסתברות להפעלה לא מכוונת.

ישנם הבדלים קלים בצורת העט מגרסתה הקודמת. להלן תמונות להמחשה:

תמונת עט עם מנגנון משופר:



תמונת עט עם המנגנון הקודם:



❖ **HUMIRA (adalimumab)** הינו נוגדן אנטי TNF הומאני מלא הניתן בהזרקה תת-עורית עצמית של החולה.

❖ **HUMIRA בעט מוכן להזרקה** מהווה דרך מתן קלה ונוחה לשימוש עצמי.

העלון לרופא והעלון לצרכן מפורסמים במאגר התרופות שבאתר משרד הבריאות וניתן לקבלו מודפס על ידי פניה לבעל הרישום Abbvie biopharmaceuticals Ltd, ישראל מגדלי הוד השרון רחוב החרש 4 בניין D הוד השרון או בטלפון 09-7909641.

Rheumatoid arthritis

Humira in combination with methotrexate, is indicated for:

- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.
- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.

Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.

Crohn's disease

Humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. Humira is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

Psoriasis

Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.

Psoriatic arthritis

Humira is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Humira has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function.

Polyarticular juvenile idiopathic arthritis

Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Humira has not been studied in children aged less than 4 years

Ulcerative colitis

Humira is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Axial spondyloarthritis

Humira is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.

Axial spondyloarthritis without radiographic evidence of AS:

Humira is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by radiological and/or laboratory tests including MRI and serum CRP levels, who have had an inadequate response to, or are intolerant to non - steroidal anti-inflammatory drugs.

Paediatric Crohn's Disease

Humira is indicated for the treatment of severe active Crohn's disease in paediatric patients (6-17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a



corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies.

OFFICE ADDRESS:

AbbVie Biopharmaceuticals Ltd.
Hod Hasharon Towers,
4 Hacharash Street, Bldg. D,
Neve Ne'eman
Hod Hasharon, 4524075
Israel

MAILING ADDRESS:

AbbVie Biopharmaceuticals Ltd.
P.O. Box 1014
Hod Hasharon, 4511001
Israel

OFFICE +972.9.790.9600

FAX +972.9.790.9606